Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer Meeting Abstract
| Authors: | Tabernero, J.; van Geel, R.; Bendell, J. C.; Spreafico, A.; Schuler, M.; Yoshino, T.; Delord, J. P.; Yamada, Y.; Lolkema, M. P.; Fans, J. E.; Eskens, Falm; Sharma, S.; Yaeger, R.; Lenz, H. J.; Wainberg, Z.; Avsar, E.; Chatterjee, A.; Jaeger, S.; Demuth, T.; Schellens, J. H. M. |
| Abstract Title: | Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer |
| Meeting Title: | 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 50 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2014 Nov 18-21 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-11-01 |
| Start Page: | 199 |
| Language: | English |
| ACCESSION: | WOS:000347755700607 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(14)70732-4 |
| Notes: | Meeting Abstract: 11LBA -- 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 18-21, 2014 -- Barcelona, SPAIN -- Source: Wos |
